A vaccine developed at the Novosibirsk-based VECTOR State Research Center of Virology and Biotechnology is more likely to be shipped to the Democratic Republic of the Congo where an ongoing Ebola outbreak has already claimed 1,700 lives, VECTOR Director-General Rinat Maksyutov informed TASS, including that talks, were underway.
“The problem [of the vaccine’s deliveries to the DRC] is under consideration. Currently, the Ebola fever outbreak is raging throughout the DR Congo. At the moment, it’s the only country which wants this vaccine, and the issue is being negotiated,” Maksyutov stated, declining to comment additional.
In late June, a Russian delegation, which included VECTOR specialists, visited Kinshasa to discuss the difficulty of Ebola vaccination within the DR Congo. At the assembly, the vaccine was offered to Congolese representatives. The Russian delegation offered their help in eradicating the disease.
Later, Anna Popova, head of Russia’s consumer safety watchdog, met with Marit van Lenthe, president of Doctors Without Borders’ branch within the Netherlands (MSF Holland), on the sidelines of the Moscow Urban Health Forum. They mentioned how the vaccine could be used to immunize the scientists and doctors working within the epicenter of the outbreak.
The VECTOR center has developed and certified the Ebola vaccine that’s believed to be the safest amongst its analogues. It has been put on the official list of medicines permitted in Russia for specific immunization in opposition to the diseases caused by the Ebola virus. The peptide vaccine differs significantly from its Western analogues as extremely safe, effective, lacking any side effects, easily storable and transportable.